Physician profile
Edith Jones
NPI 1356993448
$2,933.78
in general payments reported to CMS, 2019-2025
13 companies · $710 in 2025
The $710 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $280 · 2022: $359 · 2023: $1,158 · 2024: $427 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,294.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $815.94 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Abbvie INC. | $499.26 | 2021-2025 | |
| Alkermes, INC. | $341.18 | 2021-2025 | Lybalvi, Aristada |
| E.R. Squibb & Sons, L.L.C. | $285.00 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $192.35 | 2022-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Axsome Therapeutics, INC. | $167.83 | 2023-2024 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $156.07 | 2021-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $151.75 | 2022-2024 | Ingrezza |
| Janssen Scientific Affairs, LLC | $95.70 | 2025 | Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $83.35 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $73.52 | 2021-2024 | Uzedy, Austedo |
| Lundbeck LLC | $36.62 | 2021-2023 | Rexulti |
| Indivior INC. | $35.21 | 2023 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edith Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.